Literature DB >> 26456105

GLA variation p.E66Q identified as the genetic etiology of Fabry disease using exome sequencing.

Hao Peng1, Xiaojuan Xu2, Lusi Zhang3, Xuehong Zhang4, Hexiang Peng1, Yu Zheng1, Sanchuan Luo1, Hui Guo1, Kun Xia1, Jiada Li1, Hongliang Yao5, Zhengmao Hu6.   

Abstract

Fabry disease (FD) was an X-linked lysosomal storage disorder resulting from a deficiency in glycosphingolipid catabolism caused by mutations in the α-galactosidase A gene GLA. Variant FD patients did not present with classical symptoms during childhood and were undiagnosed or misdiagnosed with other kidney diseases, such as chronic glomerulonephritis (CGN). In this study, we utilized exome sequencing and Sanger sequencing identified the variation p.E66Q of GLA completely co-segregated with the disease phenotype in a Chinese family, which previously been diagnosed as possible CGN. Female patients exhibited preferential X-chromosome inactivation (XCI) of the normal p.E66 allele, as indicated by XCI analysis. By measuring α-Gal A activity, we found that male patients in the pedigree had just little enzymatic activity while female patients had residual enzymatic activity. These patients were diagnosed with renal variant FD in subsequent clinical review. Our results directly implicated the GLA mutation p.E66Q as the genetic etiology of the Chinese renal variant FD pedigree.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Exome sequencing; Fabry disease; The GLA gene; XCI analysis; p.E66Q

Mesh:

Substances:

Year:  2015        PMID: 26456105     DOI: 10.1016/j.gene.2015.09.088

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

1.  A classic variant of Fabry disease in a family with the M296I late-onset variant.

Authors:  Shuma Hirashio; Reiko Kagawa; Go Tajima; Takao Masaki
Journal:  CEN Case Rep       Date:  2020-09-09

2.  GLA missense and promoter variants co-segregating in a Chinese family with Fabry disease.

Authors:  Zhe-Yi Dong; Qian Wang; Shu-Peng Lin; Pu Chen; Jiao-Na Liu; Shu-Wen Liu; Guang-Yan Cai; Xiang-Mei Chen; Quan Hong
Journal:  Ann Transl Med       Date:  2020-07

Review 3.  Clinical Characteristics, Renal Involvement, and Therapeutic Options of Pediatric Patients With Fabry Disease.

Authors:  Carmen Muntean; Iuliana Magdalena Starcea; Cristina Stoica; Claudia Banescu
Journal:  Front Pediatr       Date:  2022-06-01       Impact factor: 3.569

4.  Genome sequencing reveals the role of rare genomic variants in Chinese patients with symptomatic intracranial atherosclerotic disease.

Authors:  Mengmeng Shi; Xinyi Leng; Ying Li; Zihan Chen; Ye Cao; Tiffany Chung; Bonaventure Ym Ip; Vincent Hl Ip; Yannie Oy Soo; Florence Sy Fan; Sze Ho Ma; Karen Ma; Anne Y Y Chan; Lisa Wc Au; Howan Leung; Alexander Y Lau; Vincent Ct Mok; Kwong Wai Choy; Zirui Dong; Thomas W Leung
Journal:  Stroke Vasc Neurol       Date:  2021-12-08

5.  Identification of a novel GLA mutation (Y88C) in a Korean family with Fabry nephropathy: a case report.

Authors:  Yosep Chong; Minyoung Kim; Eun Sil Koh; Seok Joon Shin; Ho-Shik Kim; Sungjin Chung
Journal:  BMC Med Genet       Date:  2016-10-24       Impact factor: 2.103

Review 6.  The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations.

Authors:  Valentina Citro; Marco Cammisa; Ludovica Liguori; Chiara Cimmaruta; Jan Lukas; Maria Vittoria Cubellis; Giuseppina Andreotti
Journal:  Int J Mol Sci       Date:  2016-12-01       Impact factor: 5.923

7.  Genotype⁻Phenotype Correlation in a New Fabry-Disease-Causing Mutation.

Authors:  Agnė Čerkauskaitė; Rimantė Čerkauskienė; Marius Miglinas; Arvydas Laurinavičius; Can Ding; Arndt Rolfs; Lina Vencevičienė; Jūratė Barysienė; Edita Kazėnaitė; Eglė Sadauskienė
Journal:  Medicina (Kaunas)       Date:  2019-05-07       Impact factor: 2.430

8.  Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease.

Authors:  Chi Zhou; Jin Huang; Guanglin Cui; Hesong Zeng; Dao Wen Wang; Qiang Zhou
Journal:  BMC Med Genet       Date:  2018-12-27       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.